Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
Васкулит
Justus Ohmes, Luisa R Monne, Sara Comdühr et al. 
PDF
Interleukin-2 deprived state of regulatory T cells and their recovery by low-dose interleukin-2 in patients with inflammatory myopathies.
Arthritis Rheumatol. 2026 Mar 25. doi: 10.1002/art.70151.
Han X, Jiang Y, Gu S et al. PDF
Ann Rheum Dis. 2026 Feb;85(2):328-338. doi: 10.1016/j.ard.2025.08.012. Epub 2025 Sep 11. PMID: 40940283.
Hao Li , Xiang Lin , Jing He
The dual role of IL-2 in systemic lupus erythematosus: balancing pro-inflammatory and anti-inflammatory effects.
Cytokine. 2025 Dec:196:157032. doi: 10.1016/j.cyto.2025.157032. Epub 2025 Sep 18.
Rui Su,Tingting Zhang, Hui Wang et al. PDF
Immunology. 2024;171:324–338. DOI: 10.1111/imm.13719
Santana S, Papillion A, Foote JB, Bachus H, León B, De Miguel C, Ballesteros-Tato A. PDF
J Immunol. 2024 Oct 15;213(8):1053-1060. doi: 10.4049/jimmunol.2400264. PMID: 39195194
Jing He, Jiali Chen, Miao Miao et al.
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.ICH GCP. Реестр клинических исследований США Publications. — 2023.
Jing He, Ruijun Zhang, Miao Shao et al.
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.Реестр клинических исследований США. 1 апреля 2023 г.
Miao Miao, Xian Xiao, Jiayi Tian et al.
Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study.Реестр клинических исследований США. 3 апреля 2023 г.
Zhang R, Zhao Y, Chen X, Zhuang Z, Li X, Shen E.
Low-dose IL-2 therapy in autoimmune diseases: An update review.Int Rev Immunol. 2024 May;43(3):113-137. doi: 10.1080/08830185.2023.2274574. Epub 2023 Oct 26. PMID: 37882232.
Hernandez R, Põder J, LaPorte KM, Malek TR.
Engineering IL-2 for immunotherapy of autoimmunity and cancer.Nat Rev Immunol. 2022 Oct;22(10):614-628. doi: 10.1038/s41577-022-00680-w. Epub 2022 Feb 25. PMID: 35217787.
Miro E. Raeber, Dilara Sahin, Ufuk Karakus, Onur Boyman PDF
MedRxiv, December 4, 2022. Doi: https://doi.org/10.1101/2022.12.02.22283042
Nirschl CJ, Brodkin HR, Hicklin DJ et al.
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression.Cancer Immunol Res. 2022 May 3;10(5):581-596. doi: 10.1158/2326-6066.CIR-21-0831.
Ruihe Wu, Yanfei Mu, Jinfang Zhao et al.
Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis.Autoimmunity Reviews. — 2022. — Vol. 21, Issue 9, September, P. 103156.
Xinyu Zheng,Rui Su,Fangyuan Hu et al.
Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viremia.Autoimmunity Reviews. — 2022. — Vol. 21, November, Issue 11, , P. 103186.
Graßhoff H, Comdühr S, Monne LR et al. PDF
Front. Immunol., 01 April 2021. Sec. Immunological Tolerance and Regulation. Volume 12. — 2021.
Xiaoying Zhang, Miao Miao, Ruijun Zhang et al. PDF
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
Signal Transduction and Targeted Therapy. 2021.
Ruihe Wua , Na Li, Xiangcong Zhao, Tingting Ding et al. PDF
Autoimmunity Reviews. — 2020. — Volume 19, Issue 10, October, 102645.
Chunmiao Zhao, Yanfang Chu, Zhaoyun Liang et al.
Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.Zhao et al. BMC Immunology. — 2019. — P. 20:32.
Le Xu, Xiaolei Song, Lili Su et al. PDF
International Immunopharmacology. — 2019. — Vol. 72, P. 322-329.
Частота инфекций при лечении низкими дозами ИЛ-2 у больных СКВ.
Реестр клинических исследований США. Клиническое испытание NCT04136106. Peking University People’s Hospital. 21 октября 2019 г.
Abbas A.K., Trotta E., Simeonov D.R., Marson A., Bluestone J.A. PDF
Интерлейкин-2: механизмы регуляции и перспективы терапии.
Science Immunology. — 2018. — Vol. 3. — Issue 25. — Eaat 1482.
Abbas A.K., Trotta E., Simeonov D.R., Marson A., Bluestone J.A. PDF
Revisiting IL-2: Biology and therapeutic prospects.
Science Immunology. — 2018. — Vol. 3. — Issue 25. — Eaat 1482.
Zhanguo Li
Исследование фазы II с низкими дозами рекомбинантного человеческого IL-2 для лечения первичного синдрома Шегрена.ICH GCP. Реестр клинических исследований США. Клиническое испытание NCT02464319. – 2018.
Zhen Zhao, Xiaojuan Zhang, Lili Su et al.
Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases.International Immunopharmacology. — Volume 56. — 2018. — Pages 269-276.
Ana Luisa Perdigoto, imageLucienne Chatenoud, imageJeffrey A. Bluestone, Kevan C. Herold.
Inducing and Administering Tregs to Treat Human Disease.Front. Immunol. — 2016. — 22 January . Sec.Vaccines and Molecular Therapeutics. https://doi.org/10.3389/fimmu.2015.00654.
Jing He, Xia Zhang, Yunbo Wei et al.
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosusNat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8. PMID: 27500725.
Keirstead N., Bertinetti-Lapatki C., Knapp D. et al.
Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat.Toxicol Pathol. 2015 Oct;43(7):984-94. doi: 10.1177/0192623315601245. Epub 2015 Sep 8.
Kosmaczewska A., Ciszak L., Swierkot J. et al.
Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients With Progressive Rheumatoid Arthritis Treated With TNF-alpha Inhibitors.Inflammation. 2015 Apr;38(2):765-74. doi: 10.1007/s10753-014-9987-x.
Zhanguo Li
Пилотное исследование низких доз hrIL-2 для лечения системной красной волчанкиРеестр клинических исследований США. Клиническое испытание NCT02465580. Peking University People’s Hospital. 21 октября 2019 г.
Любошенко Т.М. PDF
Современное общество, образование и наука. Часть 4. — Тамбов. — 2014. — 163 с.
David Saadoun, Michelle Rosenzwajg, Florence Joly et al. PDF
New England Journal of Medicine. — 2011. — 365(22):2067-77.
Kharkevich G.Yu., Tsimafeyeu I.V., Demidov L.V., Semenkova E.N.
Management of paraneoplastic vasculitis by interleukin-2 in patients with metastatic renal cell carcinoma (MRCC).
UICC World Cancer Congress 2006. EDUCATION / ABSTRACT BOOK. Washington, 2006. Abstr. N 11-41. P. 102.
Lyons D J , Gao L , Mitchell E B , Mitchell D N PDF
Thorax. 1988 Dec; 43(12): 992–997. doi: 10.1136/thx.43.12.992